Small RNA

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, Mai 24, 2024
Employment, Biology, ATyr Pharma, Human, SAN, Compensated emancipation, Scar, Fibrosis, Inflammation, Small RNA, Pharmaceutical industry

These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.

Key Points: 
  • These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
  • The options are subject to the terms and conditions of the aTyr Pharma, Inc. 2022 Inducement Plan and the terms and conditions of an award agreement covering the grant.
  • aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
  • tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

Retrieved on: 
Montag, Mai 20, 2024
Small RNA, Management, Therapy, API

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024.

Key Points: 
  • REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024.
  • During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics.
  • The panel will take place on Wednesday, May 22, 2024, at 4:25 pm ET.
  • A live webcast of the event will be available here and in the Investor Relations section of the Company’s website, https://www.codexis.com/investors .

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Retrieved on: 
Donnerstag, Mai 16, 2024
Doctor of Philosophy, Toxicity, Asos, Therapy, LNC, Small RNA, Macrophage, Cell, Poster, Lecture, Vaccine

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.

Key Points: 
  • BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
  • The poster, “Intracellular Delivery of Small Oligonucleotides with Lipid Nanocrystals (LNCs): in vitro studies,” was presented by Hui Liu, PhD, Chief Technology Officer of Matinas, and is available here .
  • The poster discusses in vitro studies demonstrating the avid uptake of LNC formulations of various cytokine-targeted small oligonucleotides in murine macrophages, with up to 70% gene knockdown observed for each targeted cytokine.
  • These characteristics make LNCs a highly promising oral drug delivery platform for future applications requiring oral delivery of small oligonucleotides.”

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference

Retrieved on: 
Mittwoch, Mai 15, 2024
Patient, Phenotype, Systemic scleroderma, Myelocyte, ATyr Pharma, Autoimmunity, Scleroderma, American Thoracic Society, SAN, Conference, NRP2, Pathology, Sarcoidosis, Tissue, Macrophage, Scar, ATS, Monocyte, Poster, Fibrosis, ILD, Inflammation, Small RNA, Neuropilin, Pharmaceutical industry

The poster will be available on the aTyr website once presented.

Key Points: 
  • The poster will be available on the aTyr website once presented.
  • These findings suggest that efzofitimod may have broad therapeutic potential in diseases where myeloid cells play a central role in pathology, including ILD.
  • Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis.
  • These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.

Aphios Granted US Patent For siRNA Targeted Therapeutics for Treatment of HIV-1 and Other Diseases

Retrieved on: 
Mittwoch, Mai 15, 2024
AIDS, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, CD4, Rhesus macaque, Human, Disulfiram-like drug, HIV, Corporation, Macaque, Patent, Public, CXCR4, Superfluidity, Infection, Small RNA, Ligand, Cell, CCR5, HIV-1, RNA, Liposome, Therapy, Virus

11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.

Key Points: 
  • 11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.
  • More than 35 million people have died from AIDS, and 37 million people are living with HIV worldwide.
  • SuperFluids are used to nanoencapsulate siRNA in phospholipid liposomes and lipid nanoparticles (nanosomes) for the improved delivery of siRNA and other biologics to diseased cells.
  • Nanosomal formulation of siRNA and small molecules offers a potential avenue to improving the efficacy of siRNA constructs.

ATED Therapeutics Ltd. Finalist in Health Products Category of Fast Company’s 2024 World Changing Ideas Awards

Retrieved on: 
Dienstag, Mai 14, 2024
Medical Devices, Health, Neurology, Genetics, Pharmaceutical, Biotechnology, DBS, Education, Therapy, Deep brain stimulation, Hebrew University of Jerusalem, AI, Social justice, RNA, Politics, Climate, Small RNA, PCR

The winners and finalists of Fast Company’s 2024 World Changing Ideas Awards were announced today, highlighting fresh sustainability initiatives, cutting-edge AI developments, ambitious pursuits of social equity, and other creative projects that are helping mold the world.

Key Points: 
  • The winners and finalists of Fast Company’s 2024 World Changing Ideas Awards were announced today, highlighting fresh sustainability initiatives, cutting-edge AI developments, ambitious pursuits of social equity, and other creative projects that are helping mold the world.
  • ATED Therapeutics, Ltd. was named a Finalist in the Health Products Category for its development of a rapid (24 hr.
  • The test was developed by Professor Hermona Soreq at Hebrew University in Jerusalem and licensed from Yissum.
  • Fast Company’s Spring 2024 issue (on newsstands May 21, 2024) will unveil some of the world’s most creative minds and pioneering organizations that are seeking to disrupt the status quo.

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Genetics, Liver disease, Coronary artery disease, Research, N-Acetylgalactosamine, Weight loss, Doctor of Philosophy, Webcast, SVP, DSM-IV codes, CSO, Biomarker, Drug discovery, AATD, RNA editing, Activin and inhibin, Facial muscles, Pharmacokinetics, LNP, SAD, GSK, Serum, Duchenne muscular dystrophy, HTT, Cerebrospinal fluid, MASH, Weight, Safety, Health, RNA, Obesity, Human, Therapy, HD, Central nervous system, Clinical trial, ED50, Small RNA, Stanford University, Lof, Genomics, Exon, Science, Senior, Patient, Cardiovascular disease, MBA, PD, Lipolysis, Q&A, Pharmaceutical industry

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Revenue was $12.5 million for the first quarter of 2024, as compared to $12.9 million in the first quarter of 2023.
  • Net loss was $31.6 million for the first quarter of 2024, as compared to $27.4 million for the first quarter of 2023.
  • ET to review the first quarter 2024 financial results and pipeline updates.

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

Retrieved on: 
Mittwoch, Mai 8, 2024
University, Protein, Mouse, Cell, GLP1, Food, Seminal vesicles, RNA, Weight loss, Partnership, Medicine, B cell, Obesity, Drug Master File, Diet, Small RNA, Metabolism, Exosome, Food and Drug Administration, Pharmaceutical industry

MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its development of a novel exosome-based biologic program targeting obesity.

Key Points: 
  • (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced its development of a novel exosome-based biologic program targeting obesity.
  • BioRestorative currently anticipates initiating the formal U.S. Food and Drug Administration (“FDA”) process for this ThermoStem®-based therapeutic candidate by filing a Drug Master File (“DMF”) in the third quarter of 2024.
  • “We believe that our proprietary ThermoStem® technology platform has immense potential to develop both best-in-class and first-in-class therapies to treat obesity, such as this exosome-based biologic candidate,” said Lance Alstodt, BioRestorative’s Chief Executive Officer.
  • “While tremendous progress has been made in the fight against obesity, there is no question that significant unmet need remains.

aTyr Pharma to Present at Upcoming Investor Conferences

Retrieved on: 
Montag, Mai 6, 2024
RBC, Human, Biology, Small RNA, Inflammation, Jefferies, Fibrosis, Scar

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences.

Key Points: 
  • In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences.
  • A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at www.atyrpharma.com .
  • Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days.
  • aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

hC Bioscience Presents Preclinical Data at ASGCT Showing Strong Potential in Hemophilia A Using tRNA-based Protein Editing Platform

Retrieved on: 
Mittwoch, Mai 8, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Haemophilia, ACE, Cancer, DSM-IV codes, Bleeding, Mouse, Cell, Duchenne, IND, Patient, Gene, Society, Biology, Duchenne muscular dystrophy, Small RNA, PTC, Vaccine

hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today presented preclinical data supporting its lead program in severe hemophilia A at the American Society of Gene and Cell Therapy Annual Meeting in Baltimore, Md.

Key Points: 
  • hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today presented preclinical data supporting its lead program in severe hemophilia A at the American Society of Gene and Cell Therapy Annual Meeting in Baltimore, Md.
  • The data also show that HCB-101 can be delivered successfully via a lipid nanoparticle to target cells in the livers of mice.
  • This tRNA-based protein editing approach has the potential for application in about 20 percent of severe hemophilia A cases and could be extended across a broad spectrum of other diseases caused by nonsense mutations.
  • “We see hemophilia A as the first of many diseases that could be addressed using our tRNA-based protein editing technology, which has broad potential to functionally undo the effects of any disease-causing nonsense mutation.